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1. Introduction  
Many patients, particularly old find it 
difficult in swallowing tablets, capsules, fluids 
and subsequently do not comply with 
prescription, which results high frequency of 
resistance situated research has resulted in 
bringing out many secure, safe new drug 
delivery system.Among the several dosage 
forms developed to improve the difficulty of 
administration, the mouth dissolving tablet 
(MDT) is the most generally favored 
commercial products. (1) The oral cavity is an 
appealing site for the administration of drugs 
because of simplicity of administration. 
Several dosage forms like Tablets, Capsules, 
and Liquid preparations are administered by 
oral route. During the most recent decade, 
mouth dissolving tablet (MDT) advances that 
make tablets disintegrate in the mouth without 
chewing and additional water intake have 
drawn a lot of consideration. The MDT’s are 
also known as fast liquefying, rapid dispersing, 
rapid dissolve, rapid melt, as well as speedy 
disintegrating tablet. (2-4) MDTs can be 
prepared by various conventional methods like 
direct compression, wet granulation, molding, 
spray drying, freeze drying and sublimation. 
Firstly, MDTs disintegrate then dissolve 
quickly in the saliva without any need for 
solvents, releasing the drug. A few drugs are 
absorbed from the mouth, pharynx and 
esophagus as the saliva goes down into the 
stomach. In many cases, bioavailability of 
these drugs is significantly more than those 
observed from conventional tablet dosage 
form. (5,6) Levocetirizine is a 3
rd
-generation of 
non-sedative antihistamine drug, it is 
developed from the second-generation 
antihistamine drug (citirizine).  
Chemically, levocetirizine is the active 
enantiomer of cetirizine. Levocetirizine has 
shown own efficacy by blocking histamine 
receptors. It prevents only binding of histamine 
to its receptors site, but don’t prevent its 
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release from the mast cells. This prevents the 
release of other allergy synthetic substances 
and enhanced blood supply to the region, and 
provides relief from the typical symptoms of 
roughage fever. Levocetirizine has low oral 
bio-availability because of high first pass 
metabolism rate. (7) Hence, formulation in 
orodispersible form of levocetirizine upgrades 
the bioavailability, decreases side effects, low 
dosing, patient compliance, rapid onset of 
action with great steadiness. In the present 
work, orodispersible tablets of levocetirizine 
were prepared by direct compression method 
using Croscarmellose sodium, sodium starch 
glycollate and crosspovidone as the 
superdisintegrants. The aim of the study was to 
evaluate the effect of the superdisintegrants on 
wetting time, disintegration time and drug 
release profile of the orodispersible tablets. 
The present investigation deals with the 
improvement of an effective and stable MDT 
of Levocitrizine having sufficient hardness, 




methyl]piperazin-1-yl]ethoxy] acetic acid) 
2. Materials and Methods 
2.1 Materials  
Levocetirizine dihydrochloride obtained 
from Vardhman Pharmaceuticals (Paonta 
Sahib), Crospovidone recieved from Macleod 
Pharmaceuticals (Baddi). Other excipients 
used like Camphor, Sodium Saccharin, 
Microcrystalline Cellulose, Mannitol, 
Magnesium stearate, Talc were of 
analyticalgrade. 
2.2 Pre-formulation study  
Standardization of the drug was carried out 
using phosphate buffer pH 6.8 by UV 
spectrophotometer. Solubility analysis of drug 
in various solvents including water, organic 
solvent methanol and phosphate buffer pH 6.8, 
was carried out. 
2.3 Methods 
Levocetirizine --CD complex (1:1 molar 
ratio) was prepared by kneading method.  
Accurately weighed amount of pure drug and 
β-CD was triturated in a clean and dry mortar 
with a small volume of water-methanol solvent 
system. The thick slurry was kneaded for 45 
min and then dried at 40C. Dried mass was 
pulverized and sieved through a (#100) mesh. 
Mouth dissolving tablet of levocetirizine β–CD 
prepared by direct compression method using 
sodium starch glycolate (SSG), croscarmellose 
sodium (CCS) and crosspovidone (CP) as 
super-disintegrants. β–CD was used as 
complexing agent to improve the dissolution of 
drug. Microcrystalline cellulose (MCC) and 
crospovidone were use as binder and super 
disintegrating agent, respectively. Drug-β–CD 
complex equivalent to 10 mg of drug and all 
the excipients except magnesium stearate were 
taken in mortar. Then powder blend was mixed 
well for 15 to 30 min. The blends were passed 
through #80 sieves. Lubrication was done 
using magnesium stearate. Final blend was 
compressed into tablet by direct compression. 
Table 1 shows the composition of different 
formulation which were undertaken for 
formulating MDTs. 

































14.5 14.5 14.5 14.5 14.5 14.5  14.5 14.5 14.5 
SSG - - 10 11 12 - - 10 - 
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The excipients selected in the above trials were 
sieved through sieve no.40 and then mixed 
properly in mentioned proportions (Table 1). 
3. Evaluation parameters 
3.1 Evaluation and Ccharacterization of 
Levocetrizine β-CD complex 
The preformulation study including Bulk 
density, tapped density hausner’s ratio 
Porosity, angle of repose and Carr’s 
compressibility index were performed. 
Organoleptic properties like colour, odour and 
taste of drug were observed. FTIR study was 
carried out to determine the functional groups 
in the drug molecule levocetirizine and β-CD 
and also act as a fingerprint of the molecule.  
 Prepared tablets were evaluated for various 
parameters such as uniformity of weight, 
thickness, hardness, friability, weight 
variation, wetting time, water absorption ratio, 
disintegration time and in vitro drug release. 
Uniformity of tablets weigh was done by using 
digital weighing balance. Hardness was 
measured by monsanto hardness tester. The 
thickness of tablets was determined using 
vernier callipers. Friability was determined in 
Roche friabilator, by taking ten tablets. Drug 
release was carried out using USP Type II 
apparatus in phosphate buffer pH 6.8. (8) 
3.2 In-vitro disintegration test 
One tablet was placed in each tube of USP 
tablet disintegration test apparatus (ED-2 
SAPO, Electrolab, Mumbai, India) and the 
basket rack is poisoned in 1 litter beaker                                                    
containing distilled water at 37ºC ± 0.5ºC. The 
conditions were maintained in such way that 
the tablets remain below the surface of the 
liquid on their upward movement and descend 
not closer than 2.5 cm from the bottom of the 
beaker. The time taken for complete 
disintegration of the tablet with no palpable 
mass remaining in the apparatus was 
measured.  
3.3 Determination of wetting time 
For the determination of wetting time of the 
tablet, a circular piece of tissue paper (12 cm X 
10.75 cm) folded twice was placed in a small 
petri-dish (internal diameter 6.5 cm) 
containing 10 ml of  phosphate buffer (pH 
6.8). A tablet was placed on the paper, and the 
time for complete wetting was measured. 
Three tablets from each formulation were 
randomly selected and the average wetting 
time was recorded. (8,9) 
3.4 In- vitro dissolution studies 
The study was carried out using USP 
dissolution test apparatus II (DS 8000, Lab 
India, Mumbai, India) at 50 rpm in 900 ml of 
phosphate buffer (pH 6.8) as a dissolution 
media. The temperature was maintained at 
37±0.5ºC. The samples were withdrawn at 
predetermined time intervals of 0, 2, 4, 6, 10 
min. Aliquots (5 ml) were withdrawn, filtered 
and analysed spectrophotometrically using UV 
spectrophotometer (3000
+
, Labindia, Mumbai) 
at 233 nm. An equal amount of fresh 
dissolution medium, pre-warmed at 37±0.5ºC, 
was added after each Ssampling to maintain 
the sink condition throughout the study. 
Dissolution study was performed in triplicate 
for each batch. (10-12) 
4. Result and Discussion 
The appearance of levocitrizine is white 
odourless and slightly bitter in taste. The 
melting point and partition coefficient of drug 
is 206.66 ± 0.5 and 0.132. X-ray diffraction 
shown that complex form of drug with β-CD 
was crystalline in nature. The other 
micrometrics evaluation for all the 
formulations were also done such as Angle of 
repose, Bulk density, Tapped density, Void 
volume, Hausner’s ratio, Porosity, Carr’s 
CCS 11 - - - -  11 - - 
CP - 10 - - - - - - 10 
Mg stearate 3 2 3 2 2 3 1 2 1 
Aerosil 2 2 2 1 2 2 1 1 2 
Mannitol 18 20 17 20 15 15 22 15 10 
MCC 68 73 72 70 77 80 74 75 80 
* Complex equivalent to 5 mg of levocetirizine 
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4.1 Fourier Transformer Infrared 
Spectroscopy (FTIR) 
FTIR spectroscopy has been used to assess 
the interaction between levocetirizine and β-
CD. 
The IR spectrum of levocetirizine, β-CD, and 
physical mixture of sodium starch glycolate, 
crosspovidone, croscarmellose and mannitol 
are shown in Figure 4.1-4.4 
 
Figure 4.1 FTIR spectrum of Levocitrizine. 
 
Figure 4.2 FTIR spectrum of β-CD 
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Figure 4.4 FTIR spectrum of levocetirizine-β-CD complex. 
 
The IR spectrum of drug, polymer, physical 
mixture and other excipient did not show any 
significant change in the characteristic peaks 
of drug, which proved that the 
superdisintegrants and the other excipient were 
compatible with each other. The physical 
mixtures did not show any sign of 
discoloration and caking. Thus, the drug and 
excipient are physically compatible with each 
other. 
4.2 Post- compression parameters  
All the formulations were also evaluated for 
post compression parameters such as 
Uniformity of weight, Hardness, Thickness, 
Water absorption, Friability and their valuable 
results are shown in Table 3. 
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Table 3 Post Compression Parameters 
Formulation 
Code 
Uniformity    of 
weight 




) ± SD 
Thickness 
(mm) ± SD 
Water 
absorption  
ratio (%) ± SD 
Friability 
(% ) ± SD 
CPX1 98.51±0.04 3.40±0.32 2.69±0.23 73.00±0.17 0.862±0.40 
CPX2 100.41±0.12 3.90±0.06 2.00±0.56 65.33±0.45 0.255±0.21 
CPX3 95.01±0.22 2.90±0.03 2.34±0.04 81.16±0.62 0.50±0.33 
CPX4 92.03±0.3 3.80±0.02 2.43±0.08 91.66±0.98 0.34±0.26 
CPX5 100.01±0.16 3.16±0.08 2.83±0.04 70.08±0.72 0.851±0.11 
CPX6 98.0±0.01 2.90±0.0 4 2.16±0.07 85.00±0.09 0.255±0.18 
CPX7 90.03±0.21 3.12±0.02 2.29±0.02 83.06±0.05 0.593±0.38 
CPX8 91.04±0.12 3.20±0.12 2.99±0.05 108.33±0.68 0.341±0.26 
CPX9 89.23±0.62 2.30±0.40 2.63±0.61 95.83±0.91 0.672±0.33 
4.2.1 Invitro wetting time and disintegration 
time  
Wetting time is closely related to the inner 
structure of the tablet. The tablet prepared by 
direct compression method had the wetting 
time between 12- 38 sec. The result of the 
wetting time and disintegration test has been 
shown in table 4  
Formulation CPX5 and CPX4 had 12 and 19 
sec wetting time, respectively. It had been 
found that the formulations containing SSG 
had less wetting time and a rapid decrease in 
wetting time was observed with an increase in 
super-disintegrate concentration. Figure 4.5 
presents the relationship between wetting time 
and disintegration time of different fast 
disintegrating tablets. In-vitro dispersion 
behavior of formulation CPX 5 is presented in 
Figure 4.6 
Table 4 Comparison between wetting time and disintegration time 
Formulation code Wetting time (sec) ± SD (n=3) Disintegration time (sec) ± SD (n=3) 
CPX1 24±0.19 35±0.24 
CPX2 22±0.15 49±0.34 
CPX3 29±0.20 40±0.29 
CPX4 19±0.16 22±0.15 
CPX5 12±0.03 20±0.07 
CPX6 36±0.22 42±0.32 
CPX7 21±0.18 37±0.42 
CPX8 22±0.16 39±0.26 
CPX9 38±0.24 45±0.39 
 
Figure 4.5 Relationship between wetting time and disintegration time of different fast 
disintegrating tablets (formulation CPX1 – CPX9). 
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Figure 4.6 In-vitro dispersion behaviour of formulation CPX5,after 1 sec (A), after 4 sec (B), after 
8 sec (C), after 10 sec (D). 
4.2.2 In-vitro release  
In Dissolution studies results were shown 
the drug release profile. In which we observed 
that drug releasing profile are more than 90% 
&drug was released  within 10 min, their 
valuable data shown in  (Table 5 and 6).  
Table 5 In-vitro released rate profile of levocetrizine tablets (CPX1- CPX5) 
Time 
(min) 
Cumulative percentage drug release (mean ±SD ) (n=3) 
CPX1 CPX2 CPX3 CPX4 CPX5 
0 0 0 0 0 0 
2 36±0.23 42±0.44 47±0.43 34±0.87 41±0.98 
4 52±0.46 55±0.75 58±0.54 54±0.46 61±0.34 
6 60±1.03 73±0.05 62±0.26 65±0.66 69±0.12 
8 73±0.65 81±0.83 73±0.34 76±0.76 81±0.14 
10 89±0.45 92±0.43 90± 0.46 98±0.66 99±0.53 
Table 6 In-vitro released rate profile of levocetrizine tablets (CPX6 –CPX9) 
Time 
(min) 
Cumulative percentage drug release (mean ± SD) (n=3) 
CPX6 CPX7 CPX8   CPX9 
0 0 0 0 0 
2 26±0.44 34±0.21 28±0.73 30±0.50 
4 48±0.56 59±0.14 45±0.71 48±0.45 
6 61±0.29 68±0.27 64±0.64 63±0.22 
8 70±0.52 77±0.36 78±0.23 71±0.34 
10 85±0.22 93±0.61 95±0.45 83±0.75 
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Figure 4.7 In-vitro release rate profile of levocetirizine formulation CPX1, CPX2, CPX3 
 
Figure 4.8 In-vitro release rate profile of levocetirizine formulation CPX4, CPX5, CPX6) 
 
Figure 4.9 In-vitro release rate profile of levocetirizine formulation CPX7,CPX8,CPX9 
As the concentration of super 
disintegratents increase, the release of drug 
also increases. The result suggested that when 
concentration of sodium starch glycolate use as 
superdisintegratents increases drug release 
profile was obtained 99% (Figure 4.7 – 4.8, 
4.9).  
From the table7 it is evident that the drug 
release from the developed fast release tablets 
followed first order release kinetics.
Table 7 Release kinetic data of formulation CPX1 – CPX9 
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CPX1 0.923 0.926 
CPX2 0.934 0.939 
CPX3 0.944 0.960 
CPX4 0.913 0.927 
CPX5 0.919 0.935 
CPX6 0.839 0.912 
CPX7 0.933 0.971 
CPX8 0.940 0.951 
CPX9 0.939 0.958 
 
 
Figure 4.10 First order release profiles of levocetirizine formulation CPX1– CPX9
5. Conclusion 
The orodispersible tablets of levocetirizine 
dihydrochloride were prepared by direct 
compression method. Various combinations of 
Sodium Starch Glycolate, Croscarmellose 
sodium and Crospovidone were used as the 
superdisintegrants for formulating the 
orodispersible. It was seen that increasing the 
concentration of the superdisintegrants 
decreased the wetting time and disintegration 
time of the formulations. The combination of 
SSG & CP was more effective in decreasing 
the disintegration time as compared to the 
combination of SSG & CCS and CP & CCS. 
The in-vitro dissolution study showed that the 
formulation containing SSG (6%) and CP 
(4.5%) was more effective in enhancing the 
rate of drug release from the orodispersible 
tablets. The comparison of the effect of 
individual superdisintegrant on the wetting 
time, disintegration time and dissolution 
showed that SSG was more suitable for the 
formulation of orodispersible tablets of 
levocetirizine dihydrochloride as compared to 
other superdisintegrants used in the current 
study. Hence from the present study, it can be 
concluded the superdisintegrant SSG and CP 
in appropriate concentration can be used to 
develop orodispersible tablets of levocetirizine 
dihydrochloride by direct compression method. 
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